{"id":62725,"title":"Prediction markets raise insider trading concerns for private biotechs","publisher":"Stockmark.IT","author":"Stockmark.IT Website","published":"2026-10-31T05:53:56+00:00","modified":"2026-10-31T05:53:56+00:00","canonical_url":"https://stockmark.it/prediction-markets-herald-insider-trading-risks-for-private-biotechs/","markdown_url":"https://stockmark.it/prediction-markets-herald-insider-trading-risks-for-private-biotechs.md","json_url":"https://stockmark.it/prediction-markets-herald-insider-trading-risks-for-private-biotechs.json","category":"Biotech","categories":["Biotech","Trading"],"featured_image":"https://i0.wp.com/stockmark.it/wp-content/uploads/2026/10/prediction-markets-raise-insider-trading-concerns-for.png?fit=1536%2C1024&quality=80&ssl=1","format":"news","language":"en-GB","content":"The emergence of prediction markets within the pharmaceutical sector has introduced new financial pathways while simultaneously elevating risks related to market integrity. These platforms allow participants to purchase stakes in the outcomes of specific events, a practice that has historically been confined to sports and geopolitical affairs. However, the landscape shifted in May 2026 when Kalshi and Polymarket, the two largest platforms in this space, began offering odds on events related to drug development. This development has prompted scrutiny from industry observers who argue that the financialisation of clinical outcomes creates an environment conducive to misuse of non-public information.\n\nAs of 30 October 2026, these platforms are facilitating significant financial activity around specific regulatory decisions. Kalshi currently offers odds on the timing of the US Food and Drug Administration’s approval of Eli Lilly’s retatrutide, while Polymarket provides similar contracts regarding the approval date for Moderna’s melanoma vaccine, intismeran autogene. Participants are able to wager substantial sums, potentially hundreds of thousands of dollars, on these potential outcomes. While Kalshi has stated that such odds are intended to address information silos in drug development by making data more publicly available, critics contend that the primary effect is to create a venue for speculation on medicines that may be life-saving.\n\nLegal experts have indicated that the presence of prediction markets in the clinical space is likely to be permanent, necessitating adaptation from both developers and regulators. Chelsea Anderson and Noah Solowiejczyk, partners at the US law firm Fenwick, note that even private drug developers are now exposed to risks associated with insider trading. They argue that the current regulatory framework, which is designed to protect public capital markets, is not fully applicable to the private sector. This gap creates challenges in ensuring that trading in prediction markets is conducted in a fair and equitable manner, particularly given the technical nature of the underlying scientific data.\n\nThe technical complexity of drug development presents a specific challenge for these markets. Anderson observed that it is difficult for laypeople to assess the likelihood of success for clinical trials, a task that even many scientists find challenging. Consequently, the value of public prediction markets as indicators of success is viewed with scepticism by some. Solowiejczyk countered that public signals from these markets are likely to influence investor behaviour and corporate decision-making, noting that prediction markets have historically been accurate predictors of outcomes in other sectors. He suggested that it would be difficult for private investors to dismiss these market signals as irrelevant, regardless of the technical barriers.\n\nThere are also concerns that the visibility of market sentiment could distort clinical trial processes. Critics within the pharmaceutical industry have raised the possibility that companies might terminate trials early if they perceive the market turning against them, driven by concerns over stock price impacts. This dynamic adds a layer of financial pressure to scientific decision-making that did not previously exist in the same form. The integration of these markets also reflects a broader criticism of capital markets, which have long lacked liquidity and meaningful participation opportunities for individuals in private markets.\n\nRegulatory oversight is expected to evolve in response to these developments. Solowiejczyk highlighted that the Commodity Futures Trading Commission may limit the types of event contracts permitted in the healthcare industry if public policy reasons warrant such restrictions. Both Anderson and Solowiejczyk agreed that while prediction markets are unlikely to disappear entirely, their character and the specific subjects available for betting will likely shift as regulators gain a more nuanced understanding of the sector. The future of these markets will depend on how effectively regulators can balance the desire for market transparency with the need to prevent insider trading and protect the integrity of the pharmaceutical development process."}